[go: up one dir, main page]

WO2001036039A3 - Iontophoretic transdermal delivery of peptides - Google Patents

Iontophoretic transdermal delivery of peptides Download PDF

Info

Publication number
WO2001036039A3
WO2001036039A3 PCT/EP2000/011318 EP0011318W WO0136039A3 WO 2001036039 A3 WO2001036039 A3 WO 2001036039A3 EP 0011318 W EP0011318 W EP 0011318W WO 0136039 A3 WO0136039 A3 WO 0136039A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
transdermal delivery
iontophoretic transdermal
iontophoretic
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/011318
Other languages
French (fr)
Other versions
WO2001036039A2 (en
Inventor
Parminder Bobby Singh
Puchun Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Original Assignee
Novartis Erfindungen Verwaltungs GmbH
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Erfindungen Verwaltungs GmbH, Novartis AG filed Critical Novartis Erfindungen Verwaltungs GmbH
Priority to AU12807/01A priority Critical patent/AU1280701A/en
Publication of WO2001036039A2 publication Critical patent/WO2001036039A2/en
Publication of WO2001036039A3 publication Critical patent/WO2001036039A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0432—Anode and cathode
    • A61N1/044—Shape of the electrode
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0432—Anode and cathode
    • A61N1/0436—Material of the electrode
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0448—Drug reservoir

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

A method is disclosed for iontophoretically delivering a drug to a mammal, wherein the drug delivery profile may be adjusted by adjusting the concentration of electrolyte in the reservoir solution of the iontophoretic system.
PCT/EP2000/011318 1999-11-17 2000-11-15 Iontophoretic transdermal delivery of peptides Ceased WO2001036039A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU12807/01A AU1280701A (en) 1999-11-17 2000-11-15 Iontophoretic transdermal delivery of peptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16615099P 1999-11-17 1999-11-17
US60/166,150 1999-11-17

Publications (2)

Publication Number Publication Date
WO2001036039A2 WO2001036039A2 (en) 2001-05-25
WO2001036039A3 true WO2001036039A3 (en) 2002-03-07

Family

ID=22602026

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/011318 Ceased WO2001036039A2 (en) 1999-11-17 2000-11-15 Iontophoretic transdermal delivery of peptides

Country Status (2)

Country Link
AU (1) AU1280701A (en)
WO (1) WO2001036039A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
EP1595542A1 (en) * 2004-03-26 2005-11-16 Solvay Pharmaceuticals B.V. Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds
US7596407B2 (en) 2004-03-26 2009-09-29 Solvay Pharmaceuticals, B.V. Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds
DK2568806T3 (en) 2010-05-12 2016-08-15 Radius Health Inc therapy Programs
EP2621901B1 (en) 2010-09-28 2015-07-29 Radius Health, Inc Selective androgen receptor modulators
EP3834824B1 (en) 2014-03-28 2025-10-22 Duke University Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator
CN113750091B (en) 2015-04-29 2025-03-11 雷迪厄斯制药公司 Methods for treating cancer
KR20220035276A (en) 2016-06-22 2022-03-21 일립시스 파마 리미티드 Ar+ breast cancer treatment methods
US10385008B2 (en) 2017-01-05 2019-08-20 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD1901-2HCL
AU2019297421B2 (en) 2018-07-04 2024-08-29 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD 1901-2HCL
CN113348163B (en) 2019-02-12 2024-10-08 雷迪厄斯制药公司 Methods and compounds
WO2022119391A1 (en) * 2020-12-03 2022-06-09 바이오센서연구소 주식회사 Formulation composition for transdermal delivery of peptides for improving transdermal delivery of peptides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0643981A1 (en) * 1993-09-22 1995-03-22 Takeda Chemical Industries, Ltd. A matrix for iontophoreses
US5961482A (en) * 1986-07-25 1999-10-05 Rutgers, The State University Of New Jersey Iontotherapeutic device and process and iontotherapeutic unit dose

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961482A (en) * 1986-07-25 1999-10-05 Rutgers, The State University Of New Jersey Iontotherapeutic device and process and iontotherapeutic unit dose
EP0643981A1 (en) * 1993-09-22 1995-03-22 Takeda Chemical Industries, Ltd. A matrix for iontophoreses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
S.-L. CHANG ET AL.: "The effect of electroporation on iontophoretic transdermal delivery of calcium regulating hormones", JOURNAL OF CONTROLLED RELEASE, vol. 66, no. 2,3, May 2000 (2000-05-01), Amsterdam (nl), pages 127 - 133, XP004193062 *

Also Published As

Publication number Publication date
AU1280701A (en) 2001-05-30
WO2001036039A2 (en) 2001-05-25

Similar Documents

Publication Publication Date Title
WO2001036039A3 (en) Iontophoretic transdermal delivery of peptides
EP0836512B1 (en) Electrotransport agent delivery apparatus
Merino et al. Electrorepulsion Versus Electroosmosis: Effect of pH on the lontophoretic Flux of 5-Fluorouracil
KR100856693B1 (en) Transdermal Electrotransport Delivery Device Including Antimicrobial Compatibility Receptacle Composition
US5464387A (en) Transdermal delivery device
CA2213347C (en) Composition and method of enhancing electrotransport agent delivery
IL144728A0 (en) Iontophoresis, electroporation and combination patches for local drug delivery
EP0643981B1 (en) A matrix for iontophoreses
AUPR148400A0 (en) Apparatus for delivery of pharmaceuticals to the cochlea
US20060184093A1 (en) Methods of electrotransport drug delivery
IL174573A0 (en) Method and apparatus for controlling extra-systolic stimulation (ess) therapy using ischemia detection
AU9035698A (en) Pharmacologic drug combination in vagal-induced asystole
AU1773792A (en) Device for reducing sensation during iontophoretic drug delivery
WO2003063961A3 (en) Method and arrangement for using atrial pacing to prevent early recurrence of atrial fibrillation
WO1997047355A1 (en) Reduction of skin sensitization in electrotransport drug delivery
WO2000066066A3 (en) Method and devices for creating a trap for confining therapeutic drugs and/or genes in the myocardium
WO2003039622A3 (en) Novel iontophoretic drug delivery systems
AU4335797A (en) Iontophoretic drug delivery system, including method for determining hydration of patch
Gratieri et al. Non-invasive iontophoretic delivery of peptides and proteins across the skin
AU7662400A (en) Transdermal therapeutic system containing tulobuterol hydrochloride for administering the bronchodilator tulobuterol via the skin
AU4428597A (en) Iontophoretic drug delivery system, including method for activating same
CN101384297A (en) Iontophoretic transdermal delivery of nicotine salts
NO20000814L (en) Identification of adhesive surface-shaped dermal and transdermal therapeutic dosage forms using an adhesive patch as an information carrier, as well as methods of their preparation
WO2005084275A3 (en) Iontophoretic electrode
JP2008501434A (en) System and method for transdermal delivery of anticoagulants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)